-
1
-
-
0035300479
-
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
-
Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
-
(2001)
Cancer Res
, vol.61
, pp. 3071-3076
-
-
Hideshima, T.1
Richardson, P.2
Chauhan, D.3
-
2
-
-
20444433230
-
Bortezomib or high dose dexamethazone for relapsed multiple myeloma
-
Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high dose dexamethazone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.W.3
-
3
-
-
77649092410
-
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma
-
Jakubowiak A.J., Kendall T., Al-Zoubi A., et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009, 27:5015-5022.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5015-5022
-
-
Jakubowiak, A.J.1
Kendall, T.2
Al-Zoubi, A.3
-
4
-
-
33846688196
-
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors
-
Cheriyath V., Jacobs B.S., Hussein M.A. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs R D 2007, 8:1-12.
-
(2007)
Drugs R D
, vol.8
, pp. 1-12
-
-
Cheriyath, V.1
Jacobs, B.S.2
Hussein, M.A.3
-
5
-
-
47949089799
-
Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
-
Lü S., Yang J., Song X., et al. Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 2008, 326:423-431.
-
(2008)
J Pharmacol Exp Ther
, vol.326
, pp. 423-431
-
-
Lü, S.1
Yang, J.2
Song, X.3
-
6
-
-
67049107847
-
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line
-
Lü S., Yang J., Chen Z., et al. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp Hematol 2009, 37:831-837.
-
(2009)
Exp Hematol
, vol.37
, pp. 831-837
-
-
Lü, S.1
Yang, J.2
Chen, Z.3
-
7
-
-
52049086674
-
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from Jurkat line
-
Lü S., Chen Z., Yang J., et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 2008, 36:1278-1284.
-
(2008)
Exp Hematol
, vol.36
, pp. 1278-1284
-
-
Lü, S.1
Chen, Z.2
Yang, J.3
-
8
-
-
53049106912
-
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein
-
Oerlemans R., Franke N.E., Assaraf Y.G., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
-
(2008)
Blood
, vol.112
, pp. 2489-2499
-
-
Oerlemans, R.1
Franke, N.E.2
Assaraf, Y.G.3
-
9
-
-
77955712506
-
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress
-
Ri M., Iida S., Nakashima T., et al. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 2010, 24:1506-1512.
-
(2010)
Leukemia
, vol.24
, pp. 1506-1512
-
-
Ri, M.1
Iida, S.2
Nakashima, T.3
-
10
-
-
77954368003
-
G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation
-
Yang Y.M., Lee S., Nam C.W., et al. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation. Carcinogenesis 2010, 31:1230-1237.
-
(2010)
Carcinogenesis
, vol.31
, pp. 1230-1237
-
-
Yang, Y.M.1
Lee, S.2
Nam, C.W.3
|